Polyrizon Ltd. Ordinary Shares PLRZ 深 沪
已收盘 10-10 16:00:00 美东时间
1.12
-0.130
-10.40%
华盛通- 最 高1.25
- 今 开1.23
- 成交量 49.03万股
- 最 低 1.12
- 昨 收 1.25
- 总市值 596.77万
- 52周最高 1200.00
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.55
- 委 比 52.55%
- 总股本 532.83万
- 历史最高 1200.00
- 量 比 0.48
- 振 幅 10.40%
- 历史最低 0.80
- 每 手 1
- 风险率 165.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Polyrizon Releases Pre-Clinical Results For Its PL-14 Allergy Blocker Showing That PL-14 Effectively Blocked The Penetration Of Der P 1, A Major House Dust Mite Allergen
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results
10-06 20:24
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. announced positive results from a pre-clinical study demonstrating the effectiveness of its PL-14 Allergy Blocker in preventing household dust mite allergen (Der p 1) penetration. After one hour, only 1.07% of the allergen passed through, with minimal penetration at two hours (1.14%) and 13.6% after four hours. The study used allergen loads tens of times higher than typical real-world exposure, suggesting strong protection. The All...
10-06 12:21
Polyrizon Advances Allergy Treatment with FDA Submission for PL-14
An announcement from Polyrizon Ltd. ( ($PLRZ) ) is now available. On September ...
09-19 20:57
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Ltd. has submitted its full pre-submission package to the FDA for its PL-14 allergy blocker, a nasal spray designed to provide long-lasting relief from allergic rhinitis by forming a physical barrier against allergens. This submission marks a significant step in the Company's regulatory strategy and addresses a critical unmet need in allergy treatment. PL-14 aims to alleviate mild allergic symptoms caused by airborne allergens such as p...
09-19 12:15
Polyrizon shares are trading higher after the company announced preclinical results for its PL-14 Allergy Blocker.
Polyrizon shares are trading higher after the company announced preclinical res...
09-12 20:38
Polyrizon shares are trading higher after the company announced it regained Nasdaq compliance.
Polyrizon shares are trading higher after the company announced it regained Nas...
08-14 23:53
Polyrizon Regains Compliance With Nasdaq Listing Requirements
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor
08-14 20:44
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Ltd. (Nasdaq: PLRZ) announced it has regained compliance with Nasdaq listing requirements, allowing it to continue trading on the Nasdaq Capital Market under the ticker "PLRZ." The company met the minimum bid price requirement and satisfied conditions set by the Nasdaq Hearings Panel. Polyrizon specializes in developing intranasal hydrogel products, including its Capture and ContainTM (C&C) technology, designed to form a protective barr...
08-14 12:14
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results.
07-23 17:00
Polyrizon Achieves Breakthrough in Allergy Blocker Study
An update from Polyrizon Ltd. ( ($PLRZ) ) is now available. On July 22, 2025, P...
07-22 21:27
